NCT06492707View on ClinicalTrials.gov

DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hematopoietic Cell Transplantation, the DR. DREAM Trial

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 23, 2024

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2027

Conditions
Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic Syndrome
Interventions
BIOLOGICAL

Decoy-resistant interleukin-18

Given SC

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Simcha Therapeutics
All Listed Sponsors
collaborator

Simcha Therapeutics

UNKNOWN

lead

Fred Hutchinson Cancer Center

OTHER